IDH1 and acute myeloid leukemia: Early clinical trials of IDH1/IDH2 inhibitors with induction chemotherapy have shown promising results, instilling a sense of optimism to increase responses and survival of IDH1-mutated AML patients fit for intensive chemotherapy [106].